Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript
Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
/PRNewswire/ -- Immunic, Inc. (NASDAQ: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 22.02.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immun...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023